LCL161

For research use only.

Catalog No.S7009

12 publications

LCL161 Chemical Structure

Molecular Weight(MW): 500.63

LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).

Size Price Stock Quantity  
USD 147 In stock
USD 477 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's LCL161 has been cited by 12 publications

2 Customer Reviews

  • Parental or rVCR RD cells were either left untreated (UT) or exposed to 40 μM of LCL161 in the absence or presence of PSC-833 (10 μM) for 48 h before analysis of DNA fragmentation using PI staining and flow cytometry (data shown are mean + SD, n = 3). *, p < 0.05, **, p < 0.01, ***, p < 0.001.

    Cancer Lett, 2018, 440-441:126-134. LCL161 purchased from Selleck.

    The Smac mimetic LCL-161, which inhibits cIAP1, modestly sensitizes hair cells to gentamicin damage. (A) Variable LCL-161 concentrations do not affect toxicity to 50 μM neomycin (one-way ANOVA, F4,69 = 1.54, p = 0.199). (B) Variable LCL has a modest but significant effect on gentamicin toxicity (one-way ANOVA, F4,31 = 3.14, p = 0.028), with 10 μM LCL conveying significant sensitization (∗p < 0.05).

    Front Cell Neurosci, 2017, https://doi.org/10.3389/fncel.2017.00326. LCL161 purchased from Selleck.

Purity & Quality Control

Choose Selective IAP Inhibitors

Biological Activity

Description LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
Targets
cIAP [1] XIAP [1]
In vitro

LCL161 binds to inhibitors of apoptosis proteins (IAPs) with high affinity and initiates the destruction of cIAP1 and cIAP2, which further induces apoptosis via caspase activation. LCL161 modestly inhibits the growth of FLT3-ITD-expressing cells when administered alone, with an IC50 ranging from ~0.5 μM (Ba/F3-FLT3-ITD cells) to ~4 μM (MOLM13-luc+ cells). The potency of LCL161 against the D835Y mutant is observed to be considerably higher, with an IC50 of ~50 nM when tested against Ba/F3-D835Y cells. Treatment of MOLM13-luc+ cells with a combination of LCL161 and PKC412 leads to significantly more killing of cells than either agent alone, with Calcusyn combination indices suggestive of synergy. PKC412 and LCL161 induces apoptosis of MOLM13-luc+ cells. The combination of PKC412 and LCL161 leads to a higher induction of apoptosis than either agent alone. LCL161 is able to override stromal-mediated rescue of mutant FLT3-expressing cells through positive combination with PKC412. LCL161 inhibits the growth of Ba/F3.p210 cells with an IC50 of ~100 nM. The combination of LCL161 and the ABL inhibitor, imatinib, is observed to be synergistic against BCR-ABL-expressing cells. LCL161 also has demonstrated activity against drug-resistant cells expressing point mutations in the target proteins. LCL161 at 1000 nM is able to mostly or completely kill Ba/F3-derived cell lines conferring resistance to PKC412, which express FLT3-ITD harboring point mutations in the ATP-binding pocket of FLT3. LCL161 also shows activity at concentrations ranging from 100 to 1000 nM against Ba/F3 cells expressing various imatinib- and nilotinib-resistant BCR-ABL point mutations. [1] LCL161 is evaluated against the 23 cell lines in the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr. LCL161 achieves 50% growth inhibition against only 3 of the 23 tested PPTP cell lines under concentration of 10 μM. The three cell lines includes two T-cell ALL cell lines (COG-LL-317 and CCRF-CEM) and an anaplastic large cell lymphoma cell line (Karpas-299), with CCRF-CEM and Karpas-299 showing the lowest relative IC50 values (0.25 and 1.6 μM, respectively). [2] LCL161shows immunomodulatory properties on human immune subsets. T lymphocytes treated with LCL161 demonstrates significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhances priming of naïve T cells with synthetic peptides in vitro. Myeloid dendritic cells undergoes phenotypic maturation upon LCL161 and demonstrates a reduced capacity to cross-present a tumor antigen-based vaccine. These effects are potentially mediated through an observed activation of the canonical and non-canonical NF-κB pathways, following LCL161 with a resulting upregulation of anti-apoptotic molecules. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LOX cells M{nlZ2N6fG:2b4jpZ:Kh[XO|YYm= M{mySlMvOyEQvF2= NYiwd2YxOyCmYYnz M1TkUXBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxQYCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgN{Bl[Xm|IHL5JG1VWyCjc4PhfS=> M4DIc|I1ODh|N{iy
human BxPC3 cells NWjpOJFjS3m2b4TvfIlkyqCjc4PhfS=> MYqzMlMh|ryP MX21JIRigXN? M{\hXXBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJ5WEN|IHPlcIx{KGG2IEOuN{B2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 MUiyOFA5Ozd6Mh?=
human LS180 cells M4DneWN6fG:2b4jpZ:Kh[XO|YYm= MnPNN{4{KM7:TR?= MlvwOUBl[Xm| NVzWN|gxWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFNzOECgZ4VtdHNiYYSgN{4{KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? MYKyOFA5Ozd6Mh?=
human HCT15 cells NFXP[2VEgXSxdH;4bYPDqGG|c3H5 MYezMlMh|ryP MUG1JIRigXN? MWXQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> NYnxU|h4OjRyOEO3PFI>
human H460 cells MonuR5l1d3SxeHnjxsBie3OjeR?= Mkf0N{4{KM7:TR?= M4DmPFUh\GG7cx?= MoT4VI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> Mme3NlQxQDN5OEK=
human SW620 cells MkjkR5l1d3SxeHnjxsBie3OjeR?= NHrR[JE{NjNizszN NGLneJI2KGSjeYO= NWjYNlMzWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1d4MkCgZ4VtdHNiYYSgN{4{KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? MnOxNlQxQDN5OEK=
human SW620 cells NUXFSphGS3m2b4TvfIlkyqCjc4PhfS=> NUfzS4F{OS5zIN88US=> MX[1JIRigXN? MlPBVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3c3OjBiY3XscJMh[XRiMT6xJJVOKGGodHXyJFUh\GG7czDifUBOXFNiYYPzZZk> M4nYN|I1ODh|N{iy
human Capan1 cells M3;oeWN6fG:2b4jpZ:Kh[XO|YYm= NHXqNJQzNjVizszN NYfPTIY3PSCmYYnz NEezfnJRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iaIXtZY4hS2GyYX6xJINmdGy|IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 M1HOWlI1ODl|OUSw
human SKMES1 cells Mom1R5l1d3SxeHnjxsBie3OjeR?= M4X0eFIvPSEQvF2= NFTzfHc2KGSjeYO= MY\Qc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDhdI9xfG:|aYOgbY4hcHWvYX6gV2tOTVNzIHPlcIx{KGG2IEKuOUB2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 NXPGRXA5OjRyOUO5OFA>
human PC3 cells M4WyfWFxd3C2b4Ppd{Bie3OjeR?= MWqyMlUh|ryP MUC1JIRigXN? M1H4eGlv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{B1dyClb37heJVufW2jYj3pcoR2[2WmIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= NXjQV2lwOjRyOUO5OFA>
human AGS cells Mlu0RZBweHSxc3nzJIF{e2G7 NFH6e3IzNjVizszN NXnrO5pIPSCmYYnz MYfJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDBS3Mh[2WubIOgeI8h[2:wYYT1cZVu[WJvaX7keYNm\CCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? MX2yOFA6Ozl2MB?=
human U118MG cells MnW5RZBweHSxc3nzJIF{e2G7 NXWzZXMzOi53IN88US=> M2LhflUh\GG7cx?= NVXwRoxHWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[XCxcITvd4l{KGmwIHj1cYFvKFVzMUjNS{Bk\WyuczDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= NE\1TYMzPDB7M{m0NC=>
human SKMES1 cells MmqzRZBweHSxc3nzJIF{e2G7 Ml;NNk42KM7:TR?= NW[3Om12PSCmYYnz M4DUdnBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCqdX3hckBUU02HU{GgZ4VtdHNiYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[XoEoB?= NVL6dVF2OjRyOUO5OFA>
human Capan1 cells M{PEOmFxd3C2b4Ppd{Bie3OjeR?= M1XBOFIvPSEQvF2= MlrkOUBl[Xm| M1PT[HBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCqdX3hckBE[XCjbkGgZ4VtdHNiYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? NXewS4o{OjRyOUO5OFA>
human MDA-MB-231 cells NV\WXIRmTnWwY4Tpc44h[XO|YYm= MYCwMlM4NTNwMzFOwG0> MmLFNVkhcA>? MWXJcohq[mm2aX;uJI9nKGOLQWCxM|IhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gWG5H[WyyaHGgcIV3\WxiYYSgNE4{PyC2bzCzMlMhfU1iYX\0[ZIhOTliaILzJIJ6KEWOSWPBxsA> MVmyOFA6Ozl2MB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / surivivin ; 

PubMed: 27737687     


A549 and H460 cells were treated for 48 h with 0-20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting. β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
Growth inhibition assay
Cell viability; 

PubMed: 27737687     


Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
In vivo LCL161 significantly enhances the ability of PKC412 to inhibit the growth of Ba/F3-FLT3-ITD-luc+ cells in vivo. LCL161 is also shown to positively combine with the standard chemotherapeutic agents, Ara-c and doxorubicin, against FLT3-ITD-expressing cells and against D835Y-expressing cells. There is an additive effect achieved by combining both Nilotinib and LCL161 in suppressing leukemia growth. LCL161 (100 mg/kg) enhances in vivo effects of high-moderate doses of nilotinib (100 mg/kg) on leukemia burden in mice. [1] CL161 is tested against the Pediatric Preclinical Testing Program (PPTP) in vivo panels (30 or 75 mg/kg [solid tumors] or 100 mg/kg [ALL]) administered orally twice in a week. LCL161 induces significant differences in EFS distribution in approximately one-third of solid tumor xenografts (osteosarcoma and glioblastoma), but not in ALL xenografts. No objective tumor responses are observed. In vivo LCL161 demonstrates limited single agent activity against the pediatric preclinical models studied. [2]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Human T-cell ALL cell lines COG-LL-317
  • Concentrations: ~10 μM
  • Incubation Time: 96 hours
  • Method:

    In vitro testing is performed using DIMSCAN


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.74 mM)
Ethanol 20 mg/mL warmed (39.94 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 500.63
Formula

C26H33FN4O3S

CAS No. 1005342-46-0
Storage powder
in solvent
Synonyms N/A
Smiles CNC(C)C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(F)C=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03111992 Completed Drug: PDR001|Drug: CJM112|Drug: LCL161 Multiple Myeloma Novartis Pharmaceuticals|Novartis December 18 2017 Phase 1
NCT01934634 Unknown status Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel Metastatic Pancreatic Cancer US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC March 2014 Phase 1
NCT01968915 Completed Drug: LCL161|Drug: Paclitaxel Neoplasms Novartis Pharmaceuticals|Novartis November 2013 Phase 1
NCT01617668 Completed Drug: LCL161|Drug: paclitaxel Breast Cancer Novartis Pharmaceuticals|Novartis August 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IAP Signaling Pathway Map

Tags: buy LCL161|LCL161 ic50|LCL161 price|LCL161 cost|LCL161 solubility dmso|LCL161 purchase|LCL161 manufacturer|LCL161 research buy|LCL161 order|LCL161 mouse|LCL161 chemical structure|LCL161 mw|LCL161 molecular weight|LCL161 datasheet|LCL161 supplier|LCL161 in vitro|LCL161 cell line|LCL161 concentration|LCL161 nmr|LCL161 in vivo|LCL161 clinical trial|LCL161 inhibitor|LCL161 Apoptosis inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID